Options
Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe
Date Issued
2023-08
Date Available
2023-11-21T10:59:07Z
Abstract
The pharmaceutical value chain, including clinical trials, pricing, access, and reimbursement, is designed for classical monotherapies. Although there has been a paradigm shift that increases the relevance of targeted combination therapies (TCTs), regulation and common practice have been slow to adapt. We explored access to 23 TCTs for advanced melanoma and lung cancer as reported by 19 specialists from 17 leading cancer institutions in nine European countries. We find heterogeneous patient access to TCTs between countries, differences in country-specific regulations, and differences in the clinical practice of melanoma and lung cancer. Regulation that is better tailored to the context of combinational therapies can increase equity in access across Europe and promote an evidence-based and authorized use of combinations.
Sponsorship
Health Research Board
Other Sponsorship
European Fair Pricing Network (EFPN)
Type of Material
Journal Article
Publisher
Elsevier
Journal
Drug Discovery Today
Volume
28
Issue
8
Start Page
1
End Page
5
Copyright (Published Version)
2023 The Authors
Language
English
Status of Item
Peer reviewed
ISSN
1359-6446
This item is made available under a Creative Commons License
File(s)
Loading...
Name
Vancoppenolle et al (2023) Targeted combination therapies in oncology; Challenging regulatory frameworks designed for monotherapies in Europe; Drug Discovery Today.pdf
Size
422.55 KB
Format
Adobe PDF
Checksum (MD5)
fd0ba69961699860af1bc9f4cda9b225
Owning collection